C-Ray Therapeutics Achieves Key Milestone in Radiopharmaceutical Manufacturing in China
C-Ray Therapeutics (Chengdu) Co., Ltd. has reached a significant milestone in its journey as a prominent player in the radiopharmaceutical sector. On June 23, 2026, the company successfully completed extensive on-site inspections conducted by experts from the Sichuan Provincial Center for Drug Evaluation and the National Defense Science and Industry Administration. The outcome of these inspections resulted in the granting of a Radiopharmaceutical Production License under China's updated regulatory framework for outsourced pharmaceutical manufacturing.
The updated regulations focus on enhancing quality management systems, delineating responsibility allocations, and establishing robust standards for on-site inspections. This pivotal certification not only affirms C-Ray Therapeutics' adherence to regulatory guidelines but also underscores the company’s diligence in ensuring compliance, operational efficiency, and supply reliability in the realm of contract manufacturing for radiopharmaceutical products.
As the radiopharmaceutical manufacturing sector is marked by stringent requirements related to quality and intricate supply chain management, the demands on contract development and manufacturing organizations are significant. C-Ray Therapeutics has addressed these challenges by establishing a state-of-the-art manufacturing facility that adheres to modern Good Manufacturing Practices (cGMP), backed by a skilled team with extensive technical and regulatory experience. Their operational philosophy prioritizes high quality and efficiency, ensuring that products are executed to the highest standards from the first attempt.
To date, C-Ray Therapeutics has successfully completed over 100 contract research and development manufacturing organization (CRDMO) projects. These projects span the full development lifecycle, from the initial research phase to commercial production. The company's achievements indicate its preparedness to navigate the complexities associated with developing and manufacturing radiopharmaceuticals, an area that is gaining traction due to the increasing demand for innovative diagnostic and therapeutic solutions.
C-Ray Therapeutics is well-positioned with its modern facility, which covers 28,000 square meters and operates under China’s Class A Radiation Safety License. It has the capability to support over 30 different radioisotopes and has delivered numerous projects that encompass both diagnostic and therapeutic applications. Notably, they have progressed five programs to the Investigational New Drug (IND) or IND-enabling stage, while 29 programs have transitioned to investigator-initiated trials (IITs), a testament to their extensive operational competency in the field.
Moreover, the company has two programs currently in Phase III clinical trials, demonstrating a robust pipeline for future growth and innovation. Through its dedication to the advancement of radiopharmaceutical technology, C-Ray Therapeutics is not only complying with current regulations but also setting new benchmarks for quality and reliability in the industry.
As C-Ray Therapeutics navigates this complex landscape, its recent licensing will serve as a strong foundation for further regulatory submissions and the commercialization of partnered programs. With every project, the company amplifies its commitment to quality science and innovative healthcare solutions, enhancing the future of radiopharmaceuticals in China and beyond.
The updated regulations focus on enhancing quality management systems, delineating responsibility allocations, and establishing robust standards for on-site inspections. This pivotal certification not only affirms C-Ray Therapeutics' adherence to regulatory guidelines but also underscores the company’s diligence in ensuring compliance, operational efficiency, and supply reliability in the realm of contract manufacturing for radiopharmaceutical products.
As the radiopharmaceutical manufacturing sector is marked by stringent requirements related to quality and intricate supply chain management, the demands on contract development and manufacturing organizations are significant. C-Ray Therapeutics has addressed these challenges by establishing a state-of-the-art manufacturing facility that adheres to modern Good Manufacturing Practices (cGMP), backed by a skilled team with extensive technical and regulatory experience. Their operational philosophy prioritizes high quality and efficiency, ensuring that products are executed to the highest standards from the first attempt.
To date, C-Ray Therapeutics has successfully completed over 100 contract research and development manufacturing organization (CRDMO) projects. These projects span the full development lifecycle, from the initial research phase to commercial production. The company's achievements indicate its preparedness to navigate the complexities associated with developing and manufacturing radiopharmaceuticals, an area that is gaining traction due to the increasing demand for innovative diagnostic and therapeutic solutions.
C-Ray Therapeutics is well-positioned with its modern facility, which covers 28,000 square meters and operates under China’s Class A Radiation Safety License. It has the capability to support over 30 different radioisotopes and has delivered numerous projects that encompass both diagnostic and therapeutic applications. Notably, they have progressed five programs to the Investigational New Drug (IND) or IND-enabling stage, while 29 programs have transitioned to investigator-initiated trials (IITs), a testament to their extensive operational competency in the field.
Moreover, the company has two programs currently in Phase III clinical trials, demonstrating a robust pipeline for future growth and innovation. Through its dedication to the advancement of radiopharmaceutical technology, C-Ray Therapeutics is not only complying with current regulations but also setting new benchmarks for quality and reliability in the industry.
As C-Ray Therapeutics navigates this complex landscape, its recent licensing will serve as a strong foundation for further regulatory submissions and the commercialization of partnered programs. With every project, the company amplifies its commitment to quality science and innovative healthcare solutions, enhancing the future of radiopharmaceuticals in China and beyond.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.